|
| CYP450基因多态性对抗肿瘤药物影响的研究进展 |
| Department of Pharmacy, Zhejiang Cancer Hospital, Hangzhou 310022, China |
| |
| DOI： |
| 中文关键词: CYP450 基因多态性 抗肿瘤药物 |
| 英文关键词: |
| 基金项目: |
|
| 摘要点击次数: 1560 |
| 全文下载次数: 1828 |
| 中文摘要: |
| 摘 要药物代谢酶的差异是药物个体疗效和副作用差异的决定因素之一。作为I相药物代谢酶，细胞色素P450酶及其编码基因在不同种群、不同个体之间均存在着差异和突变，这种基因的多态性导致了肿瘤患者对抗肿瘤药物的敏感性及预后的不同，本文就CYP家族的基因多态性对抗肿瘤药物的药动学、药效学及不良反应的影响进行综述，以期为抗肿瘤药物的个体化给药提供参考。 |
| 英文摘要: |
| ABSTRACT The difference in drug metabolizing enzymes was one of the determinants of drug efficacy and side effects of individual differences. As a phase I drug metabolizing enzyme, Cytochrome P450, and their coding genes had their differences and mutation in different populations and different individuals. Polymorphism in this gene led to its different sensitivity to anti tumor drugs and prognosis of cancer patients. In this review, the influence of gene polymorphism of CYP family on pharmacokinetic, pharmacodynamic and adverse reaction in anti tumor drugs were summarized in order to provide a reference for the individual administration of anti tumor drugs. |
| 查看全文 查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
